Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering protein modeling and design capabilities to the biopharmaceutical, chemical, consumer products and synthetic biology industries. The company offers Cyrus Bench, a Software-as-a-Service (SaaS) platform for protein structure prediction, modeling, stabilization, and engineering and design to accelerate discovery of biologics and small molecules. Cyrus Bench is based primarily on the Rosetta software package, along with associated software. Cyrus Bench offers the advanced protein structure prediction pipeline of Rosetta and SparksX, the top structure prediction software in the bi-annual CASP competition (last held in 2016) and the weekly, continuous CAMEO competition, as well as the only protein engineering software experimentally proven to design new proteins completely via software.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/27/17 | $8,000,000 | Series A |
OrbiMed Advisors SpringRock Ventures Trinity Ventures  W Fund | undisclosed |
